KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Raw Materials for 9 consecutive years, with $11.7 million as the latest value for Q1 2026.

  • For Q1 2026, Raw Materials fell 50.05% year-over-year to $11.7 million; the TTM value through Mar 2026 reached $11.7 million, down 50.05%, while the annual FY2025 figure was $14.2 million, 40.81% down from the prior year.
  • Raw Materials hit $11.7 million in Q1 2026 for Alnylam Pharmaceuticals, down from $14.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $26.0 million in Q2 2024 and bottomed at $11.7 million in Q1 2026.
  • Average Raw Materials over 5 years is $20.9 million, with a median of $22.3 million recorded in 2022.
  • On a YoY basis, Raw Materials climbed as much as 51.25% in 2022 and fell as far as 72.81% in 2022.
  • Alnylam Pharmaceuticals' Raw Materials stood at $22.3 million in 2022, then increased by 4.62% to $23.3 million in 2023, then grew by 2.65% to $24.0 million in 2024, then crashed by 40.81% to $14.2 million in 2025, then decreased by 17.6% to $11.7 million in 2026.
  • According to Business Quant data, Raw Materials over the past three periods came in at $11.7 million, $14.2 million, and $22.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.